Bioneer made an announcement on March 19 that it recently signed an export contract with Romanian medical company SC PRAXIS MEDICA SRL for $2.4 billion worth of molecular diagnosis system ExiStation and COVID-19 diagnostic kits.
The company developed ExiStation, an integrated molecular diagnosis system, which detects changes in DNA and RNA in molecular units to diagnose diseases.
It integrated the entire process, including extraction of nucleic acid, amplification and analysis of results, to lower the cost burden and the possibility of initial misdiagnosis.
The COVID-19 diagnostic kit is a product used in the ExiStation and can detect the COVID-19 virus with high sensitivity and specification. It also obtained the European CE-IVD certification.
For the product, Bioneer has applied for emergency use approval to the Ministry of Food and Drug Safety and plans to supply it as soon as it receives permission as it is undergoing a licensing process for exports.
"It is meaningful that this is the first supply contract signed by the company since it won the European CE certification," an official of the company said. "Currently, many countries in Europe, Southeast Asia and other countries are requesting supplies."
